title: Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET.
abstract: The ability to measure amphetamine-induced dopamine release in extrastriatal brain regions in the non-human primates was evaluated by using the dopamine D-2/D-3 receptor radioligand, (18)F-fallypride. These regions included the thalamus, amygdala, pituitary, temporal cortex and frontal cortex as well as putamen, caudate and ventral striatum. The positron emission tomography (PET) studies involved control studies, which extended to 3 h, and the amphetamine-challenge studies, which involved administration of d-amphetamine (approx. 0.5-1 mg/kg, i.v.). PET data analysis employed the distribution volume ratio method (DVR) in which the cerebellum was used as a reference region. Our results show a substantial decrease in the binding potential of (18)F-fallypride in extrastriatal regions: thalamus (-20%), amygdala (-39%) and pituitary (-14%). Putamen, caudate and ventral striatum also exhibited significant decreases (-20%). The decrease in (18)F-fallypride binding in the extrastriatal regions points to the importance of dopaminergic neurotransmission in these brain regions. Furthermore, our findings support the use of (18)F-fallypride to measure extrastriatal dopamine release.
authors.affiliation: Brain Imaging Center, Department of Psychiatry and Human Behavior, University of California-Irvine, 162 Irvine Hall, Irvine, CA 92697, USA. mukherjj@uci.edu
authors.forename: Jogeshwar
authors.initials: J
authors.lastname: Mukherjee
authors.forename: Bradley T
authors.initials: BT
authors.lastname: Christian
authors.forename: Tanjore K
authors.initials: TK
authors.lastname: Narayanan
authors.forename: Bingzhi
authors.initials: B
authors.lastname: Shi
authors.forename: Daphne
authors.initials: D
authors.lastname: Collins
mesh_terms: D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D001921:Brain / Q000033:anatomy & histology / Q000000981:diagnostic imaging / Q000187:drug effects*; D001931:Brain Mapping; D015259:Dopamine Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005462:Fluorine Radioisotopes; D008253:Macaca mulatta; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods; D011759:Pyrrolidines / Q000493:pharmacokinetics* / Q000494:pharmacology*; D011869:Radioligand Assay / Q000379:methods; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D050637:Receptors, Dopamine D3; D013997:Time Factors
chemical_list: D001549:Benzamides; D015259:Dopamine Agents; D005462:Fluorine Radioisotopes; C094948:N-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D000661:Amphetamine